Best Oral GLP-1 Tablet & ODT Providers in 2026 — Ranked & Reviewed
Most compounded GLP-1 providers ship injectable vials, but a growing minority offer oral formulations — sublingual tablets, oral dissolving tablets (ODT), or other non-injectable delivery. The clinical evidence for oral compounded GLP-1s is weaker than for the FDA-approved injectable equivalents (no STEP-or-SURMOUNT-equivalent randomized trials of oral compounded semaglutide or tirzepatide), and the only FDA-approved oral GLP-1 for weight loss is Lilly's Foundayo (orforglipron), which is a completely different small-molecule chemistry. That said, ODTs and oral tablets are a reasonable option for needle-averse patients willing to accept the weaker evidence base. Below we rank every provider in our directory offering an oral compounded GLP-1 alongside or instead of injectable versions, with explicit notes on form factor and evidence quality.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Quick Picks: Top 5
Detailed Reviews
Amazon One Medical
Best for: the most authoritative branded GLP-1 channel with same-day delivery and integrated manufacturer savings
Amazon One Medical's GLP-1 Weight Loss program is the unified Amazon GLP-1 channel — One Medical clinicians prescribe FDA-approved Wegovy / Zepbound / Foundayo (no compounded products), and Amazon Pharmacy fulfills with same-day delivery in ~3,000 US cities (expanding to 4,500 by year-end 2026) plus in-office kiosk pickup at select One Medical locations. No prior One Medical membership required to enroll. Insurance accepted; cash pay also supported. Foundayo (orforglipron) launched April 9, 2026 at $25/month with insurance + Lilly Savings Card and $149/month cash pay (manufacturer coupons auto-applied). Wegovy and Zepbound pricing varies by insurance; manufacturer savings programs (NovoCare, LillyDirect) are integrated into the checkout. Distinct from telehealth platforms that route brand-name fulfillment through Amazon Pharmacy as a backend — this is the Amazon-prescribing-side program.
Score Breakdown
Pros
- ✓$1/day ($25/month) with insurance and the automatically-applied Lilly manufacturer-sponsored coupon — the cheapest brand-name Foundayo channel we've seen
- ✓Same-day delivery in nearly 3,000 US cities and towns at launch, expanding to 4,500 by year-end 2026 — most aggressive delivery footprint of any GLP-1 distribution channel
- ✓In-office, licensed-pharmacist-supported kiosks at select One Medical locations let patients walk out of an appointment with their Foundayo in hand — bypasses pharmacy lines entirely
- ✓Cash-pay $5/day ($149/month) is competitive with Ro and GoodRx for the same FDA-approved brand-name product
- ✓Real-time medication availability + transparent pricing + automatic manufacturer coupon application before checkout
- ✓Has been delivering GLP-1 medications since 2021 — operational track record on cold-chain biologic logistics
- ✓24/7 access to licensed pharmacists for clinical questions
Cons
- ✗Headline $25/month Foundayo price requires both insurance coverage AND the Lilly Savings Card — uninsured patients pay the $149/month cash price
- ✗Same-day delivery is geographically gated — outside the ~3,000 cities, delivery falls back to next-day, two-day, or three-day depending on remoteness
- ✗Pricing is set by manufacturer (Lilly, Novo Nordisk) savings programs and can change at any time
- ✗Does not offer compounded semaglutide or tirzepatide — brand-name only (Foundayo, Wegovy, Zepbound)
- ✗Wegovy / Zepbound pricing is not publicly disclosed on the Amazon One Medical landing page — it depends on insurance coverage at the prescribing visit. Plan to review final pricing at checkout before committing
- ✗One Medical clinical visits accept insurance, but copays/deductibles still apply for the Scheduled Visit; cash-pay visit pricing is also disclosed on enrollment
LillyDirect Foundayo
Best for: patients with commercial insurance who want the cheapest legal brand-name GLP-1
Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss. With the Lilly Savings Card, commercially insured patients pay $25/month; cash-pay patients pay $149-$299/month depending on labeled dose. Requires a valid US prescription from any licensed prescriber.
Score Breakdown
Pros
- ✓Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
- ✓Direct from manufacturer — no compounding, no third-party reseller
- ✓Daily oral pill, no injections, no refrigeration
- ✓Available in all 50 states
Cons
- ✗Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
- ✗Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- ✗$25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- ✗Strict empty-stomach 30-minute window may be hard for some patients to follow
Embody
Best for: lowest first-month entry pricing on compounded GLP-1s
Embody (Modern Metabolic Medicine) offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation. Aggressive first-month entry pricing with all 50 states and a 24/7 clinician messaging model led by a board-certified internal medicine CMO.
Score Breakdown
Pros
- ✓Lowest first-month entry pricing in the compounded segment ($99 first month for semaglutide, $149 for tirzepatide injection)
- ✓Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- ✓Available in all 50 states with no insurance friction
- ✓24/7 unlimited clinician messaging and dose-adjustment support included
- ✓Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Cons
- ✗Refill pricing jumps to $299/month after the first month — initial $99/$149 is an intro rate, not the ongoing cost
- ✗Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- ✗Pharmacy partners not publicly named — compounding source transparency is limited
- ✗Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
GoodRx
Best for: self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies
GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. Offers self-pay discount pricing for brand-name GLP-1 medications — Foundayo (orforglipron) starting at $149/month and Zepbound KwikPen (tirzepatide) starting at $299/month — redeemable at 70,000+ pharmacies nationwide. Also operates GoodRx Care, a telehealth arm offering GLP-1 prescriptions with online visits starting at $39.
Score Breakdown
Pros
- ✓$149/month self-pay price for FDA-approved brand-name Foundayo (orforglipron) — matches the lowest available discounted cash price at launch and is dramatically cheaper than typical retail brand-GLP-1 pricing
- ✓$299/month self-pay for FDA-approved Zepbound KwikPen — significantly under the typical Lilly cash list price
- ✓Honored at 70,000+ US pharmacies nationwide — by far the largest brick-and-mortar redemption network of any GLP-1 distribution channel we cover
- ✓No telehealth membership fee — you bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded — no compounding-pharmacy quality variability or FDA non-evaluation disclaimer
- ✓Pharmaceutical manufacturer-direct pricing model — Lilly is delivering the discounted cash price directly through GoodRx, not a third-party negotiation
- ✓GoodRx Care telehealth arm offers online GLP-1 prescriptions ($39–$70 per visit, or $19 with Gold membership) — one-stop shop for both the prescription and the discount card
Cons
- ✗Requires a valid prescription — GoodRx is a discount card, not a telehealth provider. You still need a clinician to write the script (your existing PCP, an endocrinologist, or a separate telehealth visit)
- ✗Self-pay only — does not coordinate with insurance benefits or apply toward insurance deductibles
- ✗Pricing applies only to the lowest Foundayo dose at the headline number; higher doses may carry different pricing not disclosed in the launch
- ✗Does not include compounded GLP-1s — if you want compounded semaglutide or tirzepatide, this is not the channel
- ✗GoodRx is publicly traded (NASDAQ: GDRX) and pricing is subject to change as Lilly's manufacturer-sponsored coupon program evolves
Strut Health
Best for: oral-lozenge compounded GLP-1 access
Strut Health offers LegitScript + ACHC-accredited compounded semaglutide and tirzepatide in both injectable and oral lozenge formats, shipping to 49 states. Board-certified US physicians handle prescribing with free unlimited follow-up messaging, but eligibility is gated behind a 'medical necessity' clinician determination that isn't publicly defined.
Score Breakdown
Pros
- ✓Both LegitScript and ACHC accreditation — pharmacy oversight standard most compounded GLP-1 providers don't advertise
- ✓Oral lozenge formulation available for semaglutide ($99/mo) and tirzepatide ($199/mo) — injection-free alternative
- ✓Transparent auto-refill pricing with 13–21% savings vs. one-off orders
- ✓Free unlimited follow-up messaging with board-certified US physicians
- ✓49 states covered (only Arkansas excluded as of September 2024)
Cons
- ✗'Medical necessity' eligibility gate — Strut's prescribers evaluate whether treatment is medically appropriate but the criteria are not publicly defined, so users can't self-screen before paying for a consultation
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro option
- ✗Pharmacy partners not publicly named — users can't independently verify 503A/503B compounding source
- ✗No insurance accepted — cash pay only
- ✗Phone consultation requirement varies by state (not every state mandates a synchronous visit)
WeightWatchers
Best for: Foundayo access with a structured behavior-change program
WeightWatchers offers Foundayo (orforglipron) through its Med+ program, with care delivered by the WeightWatchers Clinic affiliate medical group. Foundayo is self-pay at $149/mo for the starting dose and up to $299/mo at higher doses, billed separately from the Med+ membership ($25 first month, $74/mo after with a 12-month commitment). WW is one of the few non-pharmacy telehealth programs that lists Foundayo transparently.
Score Breakdown
Pros
- ✓One of the first non-pharmacy telehealth programs to list Foundayo transparently
- ✓Care delivered by WeightWatchers Clinic (affiliated medical group)
- ✓Supports all 6 Foundayo doses: 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg
- ✓Publishes self-pay drug price on the product page (rare for a telehealth program)
- ✓Combines pharmacotherapy with the WW Points/behavior-change program
Cons
- ✗Med+ membership ($25 first month, $74/mo ongoing) is billed separately from the drug cost — actual out-of-pocket is higher than the listed $149/mo
- ✗State availability list not published publicly — requires eligibility quiz
- ✗Insurance coverage for Foundayo not yet available per WW's own disclosure
- ✗No compounded GLP-1 option; Foundayo only
- ✗12-month Med+ commitment required to lock the introductory $25 price
Calibrate Health
Best for: patients with insurance coverage who want a year-long coaching-wrap around branded Wegovy / Zepbound / Foundayo
Calibrate Health (joincalibrate.com) is a year-long metabolic-reset weight-loss program built around branded GLP-1 medication (Wegovy, Ozempic, Zepbound, or Foundayo) plus 1:1 video coaching. Program fee is $199/month with a 12-month commitment ($597 quarterly billing); medication cost is separate (~$25/month with insurance via the manufacturer savings card, otherwise standard manufacturer pricing). Distinct from 'Oxford's Medical Weight Loss / The Calibrate Clinic' already in our directory — those are unrelated entities sharing the 'Calibrate' name.
Score Breakdown
Pros
- ✓Year-long structured program with 1:1 video coaching, registered-dietitian support, and curriculum-based behavior-change content — deeper clinical wrap than transactional telehealth providers
- ✓$199/month program fee is competitive for a coaching-included GLP-1 program; medication co-pay drops to ~$25/month with insurance + manufacturer savings card
- ✓Branded GLP-1s only (Wegovy, Ozempic, Zepbound, Foundayo) — no compounded products, no FDA gray-zone risk
- ✓Insurance navigation team works with patients to maximize coverage; reportedly accepts most major commercial plans
- ✓Money-back guarantee tied to weight-loss outcomes (10% reduction over the program year) signals confidence in the program model
- ✓Published 3-year outcomes data ('19% mean weight loss' per Calibrate's pricing page) is more transparent than most weight-loss programs
Cons
- ✗12-month commitment with quarterly billing ($597 every 3 months) is a much higher financial lock-in than month-to-month telehealth providers — not refundable mid-program
- ✗Medication cost is on top of the $199/month program fee — cash-pay patients without insurance face full manufacturer pricing for Wegovy/Zepbound on top of the program fee, which makes the all-in cost meaningfully higher than compounded-GLP-1 telehealth providers
- ✗Insurance navigation depends on actually having coverage for branded GLP-1s for weight loss — most commercial plans still don't cover Wegovy/Zepbound for obesity without medical necessity
- ✗Program is structured around branded GLP-1s; if your insurance denies coverage and you need a more affordable channel, Calibrate is meaningfully more expensive than compounded telehealth alternatives
- ✗Distinct from 'Oxford's Medical Weight Loss (The Calibrate Clinic)' already in our directory — don't confuse the two when shopping
Ro
Best for: broadest GLP-1 formulary including Foundayo on day-one of launch
Ro is one of the largest direct-to-patient telehealth companies in the US and operates the most comprehensive obesity care formulary in the category — compounded semaglutide, brand-name Wegovy and Zepbound, and as of April 9 2026, Eli Lilly's new oral GLP-1 Foundayo (orforglipron) starting at $149/month for the lowest dose plus membership.
Score Breakdown
Pros
- ✓Most comprehensive GLP-1 formulary in telehealth — compounded semaglutide, brand-name Wegovy, brand-name Zepbound, and the new oral Foundayo (orforglipron) all available on one platform
- ✓Among the first telehealth providers to launch Foundayo on day one of the Lilly partner rollout (April 9 2026)
- ✓Clinician-led plan selection — 'patients connect with a licensed provider and, if appropriate, determine which GLP-1 is the best option based on their insurance coverage, the cost, and their unique clinical needs and health goals'
- ✓Nationwide delivery network — Ro reports having served patients in 'nearly every single county in the United States, including 99% of primary care deserts'
- ✓Both cash-pay and insurance-eligible options under one roof
Cons
- ✗Foundayo on Ro requires a recurring membership in addition to the $149/mo cash drug price — total monthly cost is higher than the headline number
- ✗Specific Foundayo dose-tier pricing above the lowest dose not publicly disclosed in the launch announcement — needs intake to confirm
- ✗State availability and pharmacy partners not itemized publicly — requires signup intake to verify
- ✗Like all telehealth GLP-1 providers, Ro charges separately for the program (membership) and the medication; users sometimes confuse the bundled vs. unbundled pricing models
Curex
Best for: affordable compounded GLP-1 with strong corporate transparency and pharmacy testing
Curex (Curex, Inc.) offers compounded semaglutide ($149/mo) and tirzepatide ($199/mo) in injectable and oral dissolving tablet formats. LegitScript certified. Available in 43+ states. No membership fee. Miami and NYC offices. Originally an allergy immunotherapy company.
Score Breakdown
Pros
- ✓LegitScript certified
- ✓Named entity (Curex, Inc.) with two offices — Miami FL and NYC
- ✓Competitive pricing: semaglutide $149/mo, tirzepatide $199/mo
- ✓No membership fee ever
- ✓Injectable and oral dissolving tablet formats
- ✓Third-party lab testing via FDA/DEA certified labs
- ✓Works with LabCorp and Quest Diagnostics
- ✓43+ state coverage with transparent exclusion list
Cons
- ✗Not available in AK, AR, CT, HI, MA, NM, MO
- ✗Compounded only — explicitly states 'We don't prescribe Ozempic, Wegovy, Zepbound, or Mounjaro'
- ✗Primary business is allergy immunotherapy — GLP-1 is a newer vertical
BetterMe Rx
Best for: patients who value pharmacy transparency — six named compounding partners
BetterMe Rx offers compounded semaglutide ($199/mo) and tirzepatide ($299/mo) in both injectable and oral daily tablet formats. LegitScript verified. All 50 states. Six named pharmacy partners with phone numbers — strongest pharmacy transparency in the dataset.
Score Breakdown
Pros
- ✓LegitScript verified
- ✓All 50 states coverage
- ✓Six named pharmacy partners with phone numbers — exceptional transparency
- ✓Both injectable and oral daily tablet formats for sema and tirz
- ✓Multi-month discounts (3-month and 6-month plans)
- ✓Affiliated with Telegra MD and Dr Telx telehealth networks
Cons
- ✗No formal corporate entity name or address disclosed
- ✗Compounded only — no brand-name options
- ✗Broader platform (HRT, ED, NAD+, Sermorelin, skincare)
Vaylen
Best for: GLP-1-focused care with oral and injectable options across all 50 states
Vaylen is a pure GLP-1 specialist offering compounded semaglutide ($179/mo), compounded tirzepatide ($239/mo), compounded oral GLP-1 ($259/mo), and brand-name Ozempic, Zepbound, and Wegovy. LegitScript certified. Licensed clinicians in all 50 states.
Score Breakdown
Pros
- ✓Pure GLP-1 specialist — not a multi-category telehealth platform
- ✓All 50 states coverage with licensed clinicians
- ✓Both compounded and brand-name options (Ozempic, Wegovy, Zepbound)
- ✓Oral GLP-1 option (compounded dissolvable tablets) for needle-averse patients
- ✓LegitScript certified
- ✓Transparent pricing — no hidden costs, no insurance required
- ✓Continuous coaching and lab support included
Cons
- ✗Compounded semaglutide at $179/mo is mid-range (not the cheapest)
- ✗Brand-name options at near-retail pricing ($997–$1,350/mo)
ShedRx
Best for: mainstream telehealth GLP-1 access
Telehealth provider offering compounded GLP-1 medications in injectable, lozenge, and drop formats.
Score Breakdown
Pros
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Cons
- ✗Limited public information on program details
Kin Meds
Best for: patients who want both compounded and brand-name GLP-1 options on one platform with publicly-disclosed pricing, plus a multi-modality longevity stack — willing to verify the actual brand-name dispensing pathway during intake (whether $149 reflects commercial insurance + manufacturer savings card or a different mechanism)
Kin Meds (kinmeds.com) is a LegitScript-verified telehealth platform offering BOTH compounded GLP-1s (Personalized GLP-1 / semaglutide $199/mo, Personalized GLP-1+GIP / tirzepatide $249/mo) AND brand-name FDA-approved options (Wegovy injection + pill, Zepbound, Foundayo at $149/mo entry). Multi-modality menu includes Sermorelin, NAD+, Glutathione, TRT, hair growth, skin health, and sexual health. Verbatim regulatory disclosure: 'Medication is compounded and dispensed by a licensed third-party pharmacy. Kin Meds is not a state-licensed pharmacy nor a drug manufacturer.'
Score Breakdown
Pros
- ✓$199/mo compounded semaglutide and $249/mo compounded tirzepatide are publicly disclosed (uncommon pricing transparency)
- ✓Brand-name medications offered alongside compounded — Wegovy injection + pill, Zepbound, Foundayo all listed at $149/mo entry pricing (likely the manufacturer copay-card price for commercially insured patients)
- ✓LegitScript verification seal displayed
- ✓Verbatim regulatory disclosure clearly identifies Kin Meds as the telehealth/intake platform and the 'licensed third-party pharmacy' as the dispenser — material YMYL transparency
- ✓Multi-modality longevity menu (Sermorelin, NAD+, Glutathione) plus TRT + hair + skin + sexual health for cross-product retention
- ✓Telehealth flow (questionnaire → provider review → tailored plan → ongoing support) clearly disclosed
Cons
- ✗Specific legal entity name + state of incorporation NOT publicly disclosed
- ✗Specific 'licensed third-party pharmacy' partner NOT named (verbatim disclosure acknowledges Kin Meds is NOT itself a state-licensed pharmacy)
- ✗Per-state availability NOT enumerated
- ✗$149/mo brand-name pricing for Wegovy/Zepbound/Foundayo is the entry tier — typical floors are commercial-insurance-with-savings-card; cash-pay patients should expect higher real-world costs (NovoCare $299 sema, LillyDirect $299-$449 tirz)
- ✗First-month promotional pricing NOT disclosed
- ✗Lab work + dose-titration support NOT clearly disclosed in marketing copy
- ✗Multi-product breadth (8+ categories) signals broad DTC telehealth rather than GLP-1-specialist platform
Good Girl Rx
Best for: patients seeking multiple compounded GLP-1 formats with pharmacy quality standards
Good Girl Rx (Good Girl LLC) offers compounded semaglutide and tirzepatide in injectable, microdose, and oral dissolving tablet (ODT) formats. Brand-name Ozempic, Wegovy, Zepbound, Mounjaro also listed (limited availability). LegitScript certified. Dispensed by licensed 503A/503B pharmacies. Founded by Savannah Chrisley.
Score Breakdown
Pros
- ✓LegitScript certified
- ✓Multiple formats: injectable, microdose, and ODT pills for both semaglutide and tirzepatide
- ✓Dispensed by licensed 503A or 503B pharmacies
- ✓Brand-name options available (Ozempic, Wegovy, Zepbound, Mounjaro — limited)
- ✓Named legal entity with Nashville address
- ✓Financing via Affirm, Klarna, Afterpay
Cons
- ✗Pricing not publicly displayed — requires completing intake quiz
- ✗State availability not disclosed
- ✗Founded January 2025 — very new brand
- ✗Celebrity-founded (Savannah Chrisley) — brand credibility vs clinical credibility
OnlineSemaglutide.org
Best for: mainstream telehealth GLP-1 access
Telehealth provider offering compounded semaglutide in both injectable and oral pill formats.
Score Breakdown
Pros
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Cons
- ✗Limited public information on program details
Wellorithm
Best for: compounded GLP-1 access with oral tablet options across 49 states
Wellorithm is a Miami-based GLP-1 telehealth offering compounded semaglutide and compounded tirzepatide in both injectable and oral dissolving tablet formats. Available in 49 states (not Louisiana). Board-certified obesity specialists provide virtual consultations with 24/7 support.
Score Breakdown
Pros
- ✓Four compounded GLP-1 formats: semaglutide injectable, semaglutide oral dissolving tablets, tirzepatide injectable, tirzepatide oral dissolving tablets
- ✓Available in 49 states — broader coverage than most compounded GLP-1 telehealth providers
- ✓Board-certified obesity specialists with virtual consultations
- ✓2-minute quiz onboarding — fast async approval path
- ✓24/7 support with dedicated phone line
- ✓Katalys RevOffers tracking pixel detected — affiliate program active
Cons
- ✗Not available in Louisiana
- ✗Pricing not publicly disclosed on their website — requires completing the intake quiz
- ✗No visible LegitScript certification or PCAB accreditation
- ✗Compounded medications have not been reviewed or approved by the FDA (stated on their site)
Claya
Best for: Patients seeking a compounded GLP-1 platform with named clinician leadership and named pharmacy partners who want both injectable and oral-tablet form factors, and who are comfortable with the standard 503A-compounded supply chain.
Claya (claya.com) is a direct-to-consumer GLP-1 telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms. Compounded semaglutide injectable starts at $179/month (first month), oral tablets at $279/month; compounded tirzepatide injectable at $279/month, oral tablets at $379/month. Refills lock at $299/month. Pricing is bundled with provider consultation and 'free, expedited delivery' per the homepage. Named medical leadership: Jennifer Habashy NMD MS and Dr. Michael Barber MD PhD — unusual transparency for a compounded-GLP-1 marketplace. Pharmacy partners disclosed by name: RedRock Pharmacy (1240 E 100 S #220, St. George, UT 84790) and Healthware House (7107 Industrial Rd., Florence, KY 41042). Corporate address: 317 6th Ave Ste 400, Des Moines, IA 50309 (with alternate partner-operations address at 2345 Via Inspirada, Unit 130, Henderson, NV 89044). LLC/Inc/PC designation is NOT explicitly disclosed on the site. Tagline: 'Fat loss made easy with personalized care' with a 'Weight Loss Money Back Guarantee.' Brand-name Wegovy/Ozempic/Mounjaro/Zepbound are referenced as comparator products but Claya sells the compounded versions. Live-verified 2026-05-19.
Score Breakdown
Pros
- ✓Two named licensed clinicians (Habashy NMD MS and Barber MD PhD) — rare transparency for a compounded-GLP-1 platform
- ✓Two named 503A-pattern pharmacy partners with full addresses (RedRock UT + Healthware KY)
- ✓Both injectable AND oral-tablet compounded formulations offered for both semaglutide and tirzepatide
- ✓Weight-loss money-back guarantee published on homepage
- ✓Free expedited shipping included in monthly price
Cons
- ✗States-served list NOT disclosed on homepage or FAQ — buyers must check at checkout
- ✗LegitScript certification status NOT displayed on homepage
- ✗Corporate legal entity (LLC/Inc/PC) NOT disclosed on site or in privacy policy
- ✗Compounded oral tablets are an aggressive form factor — efficacy data vs injectable semaglutide is weaker (no STEP-equivalent oral compounded trials)
- ✗Tiered pricing structure (intro vs refill) creates first-month price advantage that disappears at refill
Eve
Best for: **Women** seeking a women's-health-focused GLP-1 telehealth platform with dual access to either affordable compounded GLP-1 ($195/mo) OR brand-name FDA-approved Ozempic / Wegovy / Mounjaro ($1,399-$1,699/mo cash-pay), with LegitScript verification and a satisfaction guarantee. Strong fit for buyers who want a single platform supporting both ends of the compounded-vs-brand-name choice without switching providers.
Eve (tryeve.co) is a women's-health-focused GLP-1 telehealth platform — distinctive positioning vs the male-default DTC market. Tagline: 'Empowering Women's Health.' DUAL-MODALITY OFFERING (rare in the WLR directory — only Brightmeds + Eve offer both): compounded semaglutide $195/month (injection + oral sublingual forms), compounded tirzepatide $195/month, PLUS brand-name FDA-approved Ozempic® $1,399/month, Mounjaro® $1,399/month, Wegovy® $1,699/month. Payment model: 'You pay $0 unless approved by a licensed physician.' Free shipping on orders above $50. Satisfaction guarantee: 'We're confident you'll love it—or your money back.' Subscription cancelable anytime. LegitScript Certified with verifiable ID 42862417. Verbatim FDA disclaimer published: 'The FDA does not review or approve any compounded medications for safety or effectiveness.' Multi-state coverage implied (verbatim: 'If you relocate to a state we currently serve, your treatment can continue seamlessly') but explicit states list NOT disclosed. Pharmacy partner, 503A vs 503B designation, named medical director, corporate legal entity, and governing law are NOT publicly disclosed. Live-verified 2026-05-19.
Score Breakdown
Pros
- ✓**Women's-health-focused brand positioning** is genuinely differentiated — most DTC GLP-1 competitors default to gender-neutral or male framing; Eve fills a real market gap
- ✓**Dual modality access** (compounded + brand-name FDA-approved) — patients who prefer Wegovy/Ozempic/Mounjaro can access them on the same platform as compounded options; rare in the DTC directory (Brightmeds is the only other one)
- ✓LegitScript Certified with publicly verifiable ID (42862417) — strong trust signal beyond just the badge
- ✓Verbatim FDA compounded-medication disclaimer published — meets WLR transparency standard
- ✓Oral SUBLINGUAL semaglutide offered alongside injectable — auto-classifies into /best/oral-glp1-providers via description regex
- ✓'$0 unless approved' payment model reduces sign-up risk significantly
- ✓Satisfaction guarantee / money-back available
- ✓Free shipping above $50 threshold (most orders qualify)
Cons
- ✗Full states-served list NOT disclosed publicly — only implied via relocation-continuity framing
- ✗Specific 503A pharmacy partner NOT named
- ✗503A vs 503B compounding designation NOT specified
- ✗LegitScript ID published (42862417) but not embedded in text — only in the seal image
- ✗Named medical director / clinical leadership NOT disclosed
- ✗Corporate legal entity (LLC/Inc/PC) NOT disclosed
- ✗Governing law / arbitration venue NOT publicly stated
- ✗Brand-name pricing ($1,399-$1,699/mo) is roughly retail cash-pay — does NOT appear to include savings card or insurance pathways; patients with insurance should price-compare elsewhere first
- ✗Subscription cancellation allowed but refund policy text not detailed publicly
Näky
Best for: patients comfortable with intake-gated pricing who want access to compounded oral semaglutide drops or an explicit microdose program alongside a longevity menu (NAD+ / Sermorelin)
Näky (benaky.com) is a LegitScript-approved telehealth platform offering compounded GLP-1s alongside oral semaglutide drops, NAD+ injections, and Sermorelin. Includes a separate GLP-1 Microdose program. Prescribing flow uses a 3-minute online assessment with same-day treatment plan from a licensed provider. Steady-state monthly pricing is gated behind the intake; a NAKY10 promo code is referenced for oral semaglutide. Pharmacy partners are described generically as 'USA Based FDA-Regulated pharmacies' but specific names are not disclosed.
Score Breakdown
Pros
- ✓LegitScript Approved seal verbatim displayed ('Verify LegitScript Approval for www.benaky.com')
- ✓Oral semaglutide DROPS as a distinct product line — uncommon among compounded GLP-1 telehealth
- ✓Explicit GLP-1 Microdose program offered as a separate SKU
- ✓Multi-modality menu (NAD+, Sermorelin) for patients seeking longevity stack alongside GLP-1
- ✓3-minute online assessment + same-day treatment plan disclosed publicly
- ✓NAKY10 promo code referenced for oral semaglutide product line
Cons
- ✗Steady-state monthly pricing for compounded semaglutide and tirzepatide NOT disclosed publicly — gated behind intake
- ✗Oral semaglutide drops pricing NOT disclosed
- ✗GLP-1 Microdose program pricing NOT disclosed
- ✗Specific legal entity name + state of incorporation NOT publicly disclosed
- ✗Partner FDA-regulated pharmacy name NOT disclosed (only generic 'USA Based FDA-Regulated pharmacies' claim)
- ✗Per-state availability NOT enumerated
- ✗Brand-name GLP-1 lineup (Wegovy/Zepbound/Mounjaro/Ozempic/Foundayo) NOT addressed — compounded only
- ✗/treatments/<slug> and /pricing routes return 404 — pricing tiers genuinely intake-gated
- ✗Initial consultation fee structure NOT disclosed publicly
- ✗Lab work + ongoing-care touchpoints NOT clearly disclosed in marketing copy
- ✗**Oral semaglutide DROPS** are not the same as Rybelsus or any FDA-approved oral semaglutide formulation — patients should ask for specific bioavailability + dose-equivalence framing during the intake; we do not endorse compounded oral GLP-1 drops as bioequivalent to FDA-approved alternatives without primary-source verification
Wisp
Best for: buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested
Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month. Reviews are completed by board-certified providers within 24-72 hours. Wisp is LegitScript certified.
Score Breakdown
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
AquaVita NextGen
Best for: patients in AZ/CA/FL/TX/NV seeking medspa-backed GLP-1 with a named medical director
AquaVita NextGen (AquaVita Wellness & Medspa) offers compounded semaglutide and tirzepatide (ODT tablets). Licensed providers in AZ, CA, FL, TX, NV. Medical Director: Dr. Steve Groke. Lake Forest, CA.
Score Breakdown
Pros
- ✓Physical address in Lake Forest CA
- ✓Named medical director (Dr. Steve Groke)
- ✓Both semaglutide and tirzepatide including ODT tablets
- ✓Compounding disclaimer present on site
Cons
- ✗Only 5 states (AZ, CA, FL, TX, NV)
- ✗Pricing not publicly displayed ($00.0 placeholders)
- ✗No LegitScript or PCAB accreditation
- ✗Primarily a local medspa expanding into telehealth
Elevated Health
Best for: affordable compounded GLP-1 with oral option
Elevated Health offers compounded semaglutide ($176/mo) and compounded tirzepatide ($238/mo). $100 off first month promotional offer. Also offers oral semaglutide.
Score Breakdown
Pros
- ✓Competitive pricing — semaglutide $176/mo, tirzepatide $238/mo
- ✓$100 off first month
- ✓Oral semaglutide option
Cons
- ✗No LegitScript or PCAB accreditation
- ✗No legal entity or address disclosed
- ✗State availability not disclosed
- ✗Shopify storefront — limited clinical infrastructure signals
NowPatient
Best for: Brand-name GLP-1 access without a compounded route
NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda. Consultations are free and patients pay only the cost of the prescribed medication, which means out-of-pocket tracks brand list prices (~$1,000-$1,350/mo without insurance). HQ Austin, TX.
Score Breakdown
Pros
- ✓Free telehealth consultation — patients only pay the medication cost
- ✓Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
- ✓One of the few telehealth platforms offering Wegovy in both injection and oral pill form
- ✓No compounded options — every drug is FDA-approved brand
Cons
- ✗Cash-pay pricing tracks full brand list price (~$1,000-$1,350/mo)
- ✗Does not offer compounded semaglutide or tirzepatide (generally the cheaper route)
- ✗State availability not disclosed publicly — determined during intake
- ✗Phone: 1-866-967-1977, HQ Austin TX
- ✗Does NOT offer Foundayo (orforglipron)
TeleHealth Med
Best for: Buyers seeking a Georgia-based, Inc.-incorporated telehealth platform with LegitScript verification, explicit 503A pharmacy designation, verbatim FDA compounded disclaimer, and honest testimonial-compensation disclosure — strong fit for transparency-conscious cash-pay patients who want HSA/FSA acceptance and both injectable and sublingual GLP-1 form options.
TeleHealth Med (telehealthmed.com) is an Evans, Georgia-based telehealth weight-loss platform offering compounded GLP-1 (semaglutide and tirzepatide) in both injectable and sublingual forms. Corporate entity EXPLICITLY disclosed: 'TeleHealth Med, Inc.' (Inc. designation in footer copyright '© 2026 TeleHealth Med, Inc. All rights reserved'). Pricing: 'As low as $147.00/month.' LegitScript Certified — verification link displayed (legitscript.com/websites/?checker_keywords=telehealthmed.com), specific ID not visible in text form. Verbatim FDA compounded-medication disclaimer published: 'The FDA has not approved or evaluated compounded medications regarding their safety, quality, or effectiveness.' Pharmacy partner (FAQ verbatim): 'Our 503A pharmacies are regulated by the FDA and also licensed by their respective state boards.' US-licensed + board-certified clinicians operating exclusively within the United States. Phone 1-833-865-8118. Email support@telehealthmed.com. HSA and FSA accepted. No insurance required. Notable: site explicitly discloses 'Testimonials are compensated. Customer images are user-submitted, and individual results have not undergone independent verification' — uncommon honest disclosure. Site disclaims: 'This website is not a pharmacy or healthcare provider. Medical services and prescription fulfillment...' Claims '100,000+ treatments successfully filled' and '98% high patient achievement rate.' Subscription cancellation allowed; refunds may be proportionally adjusted for promotional discounts; non-refundable for partially utilized subscription periods. Multiple medical-board license-verification footer links (California, Massachusetts, Rhode Island, Vermont) appear to reference state-licensure verification resources, not necessarily exhaustive states-served list. Affiliate tracking via panoramatrack.com (NOT the standard Katalys/RevOffers pattern). Captured via Chrome MCP since site 403s on WebFetch. Live-verified 2026-05-19.
Score Breakdown
Pros
- ✓Corporate Inc. entity explicitly disclosed (TeleHealth Med, Inc.) — clearer accountability than LLC-or-undisclosed competitors
- ✓Verbatim FDA compounded-medication disclaimer published — meets WLR transparency standard
- ✓503A pharmacy designation explicitly stated in FAQ (verbatim)
- ✓**Honest testimonial-compensation disclosure** — verbatim 'Testimonials are compensated. Customer images are user-submitted, and individual results have not undergone independent verification.' Uncommon honest framing vs DTC competitors that present testimonials as organic
- ✓Both injectable AND sublingual forms offered (per FAQ — auto-classifies into /best/oral-glp1-providers via description regex)
- ✓HSA / FSA accepted — uncommon in DTC compounded-GLP-1 market
- ✓Phone support published (1-833-865-8118) with business-hours coverage
- ✓LegitScript verification link active
- ✓$147/mo entry pricing is competitive with the DTC market
Cons
- ✗Specific 503A pharmacy partner NOT named (only generic '503A pharmacies' framing)
- ✗LegitScript ID NUMBER not visible in text form (only the verification link)
- ✗Full states-served list NOT explicitly disclosed — footer references CA/MA/RI/VT for license-verification resources but these are not framed as the exhaustive states-served list
- ✗Named medical director / clinical leadership NOT disclosed
- ✗Affiliate tracking uses panoramatrack.com (NOT the standard Katalys/RevOffers pattern other WLR providers use)
- ✗Pricing dose tiers beyond starting $147/mo NOT disclosed publicly
- ✗Refund policy partially restrictive — 'no refunds for partially utilized subscription periods or bundled packages'; 'Refunds for canceled services may be proportionally adjusted if initial promotional discounts'
- ✗Compounded-tirzepatide pricing NOT explicitly stated on homepage (only main heading lists 'GLP-1, Semaglutide & Tirzepatide')
- ✗Site disclaims being a pharmacy or healthcare provider — common DTC framing but worth noting for accountability-conscious buyers
- ✗'100,000+ treatments' + '98% achievement rate' claims not independently verified
Try Ageless
Best for: Cost-sensitive patients seeking the lowest-tier compounded GLP-1 prices with a LegitScript-verifiable telehealth platform, especially those who want non-injectable oral forms (drops or troche) for needle-aversion and accept the weaker oral-compounded evidence base.
Try Ageless (tryageless.com) is a longevity + metabolic health telehealth platform offering compounded semaglutide and tirzepatide in THREE form factors — injection, troche (lozenge), and drops (sublingual) — a broader form-factor range than most DTC competitors. Verbatim FDA compounded-medication disclaimer published: 'Compounded medications, including semaglutide and tirzepatide, are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality.' LegitScript Certified with verifiable ID 123956 (visible in footer seal). Pricing: Semaglutide injection $119 (discounted from $169), Tirzepatide injection $169 (from $219), Semaglutide drops $199 (from $249), Tirzepatide drops $249 (from $299), Semaglutide troche $249 (from $299) — among the more aggressive promotional pricing in the WLR directory. Corporate address: Suite 305, 131 Continental Dr, Newark, DE 19713 (DE-LLC pattern common for DTC telehealth). Brand positioning: 'Clinician-Guided Telehealth for Longevity & Metabolic Health' covering weight loss, energy, hormone support, and sexual wellness — broader scope than weight-loss-only competitors. Pharmacy partner NOT named (only 'state-licensed pharmacies' generic framing). Named medical director NOT disclosed. Live-verified 2026-05-19.
Score Breakdown
Pros
- ✓LegitScript Certified with visible ID (123956) — verifiable signal vs badge-only competitors
- ✓THREE compounded form factors offered: injection, troche, sublingual drops — broadest DTC form-factor range in the WLR directory
- ✓Verbatim FDA compounded-medication disclaimer published (uncommon transparency)
- ✓Among the lowest advertised introductory prices — semaglutide injection $119/mo is one of the cheapest tier-1 prices we track
- ✓Delaware corporate address disclosed (Suite 305, 131 Continental Dr, Newark, DE 19713)
- ✓Longevity + metabolic health positioning aligns with the broader DTC longevity-medicine trend
Cons
- ✗Introductory pricing (-17% to -30% discounts) — refill/maintenance pricing not disclosed publicly; common DTC pattern is price escalation post-introductory tier
- ✗Pharmacy partner NOT named (only 'state-licensed pharmacies' generic framing)
- ✗States-served list NOT enumerated — 'Availability depends on your state' framing
- ✗Named medical director NOT disclosed
- ✗503A vs 503B compounding designation NOT specified
- ✗Compounded oral forms (drops, troche) have weaker evidence base vs injectable — no STEP/SURMOUNT-equivalent oral compounded RCTs
- ✗Corporate legal entity (LLC/Inc/PC) NOT explicitly disclosed (Newark DE address suggests DE LLC, but designation absent)
- ✗Broad longevity-platform scope may dilute weight-loss-specific clinical focus vs specialist competitors
FuturHealth
Best for: readers who want both brand-name and compounded GLP-1 options on one platform with registered-dietitian nutrition coaching, AND are willing to read the data-breach litigation disclosure before signing up
FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added Q2 2026) plus clinician-discretionary compounded GLP-1/GIP combinations, dispensed through US-based licensed pharmacies. The platform layers digital coaching and registered-dietitian nutrition guidance on top of the medication.
Score Breakdown
Pros
- ✓LegitScript Certified and HITRUST Certified — two independently verifiable telehealth/health-data trust marks
- ✓Brand-name injection + oral pill GLP-1s on one platform: Wegovy injection, Wegovy oral pill, Zepbound, Mounjaro, Ozempic, Foundayo (orforglipron oral, added Q2 2026), plus clinician-discretionary compounded options
- ✓First-mover on dispensing Foundayo (orforglipron, FDA-approved April 2026) — earliest direct-to-consumer access to the new oral non-peptide GLP-1
- ✓Bundled registered-dietitian nutrition guidance — most pure-Rx telehealths leave nutrition support to the patient
Cons
- ✗ACTIVE LITIGATION: Wilson v. FuturHealth Inc., U.S. District Court Southern District of California, Case No. 3:2025cv00157, alleging unauthorized access to G-Plans subscriber data on/before October 16, 2024 and asserting CCPA, medical-confidentiality, and negligence claims. Material disclosure for any reader signing up.
- ✗BBB complaint pattern: multiple consumer reports of recurring unauthorized charges (e.g. $396/month) without medication being received — verify cancellation flow before subscribing
- ✗Pharmacy partners are described as 'licensed, U.S.-based pharmacies' but no specific 503A/503B partners are publicly named
- ✗Pricing is not displayed on the public landing page — visible only after qualification questionnaire/portal login
- ✗Clinical platform is white-labeled on top of SteadyMD and OpenLoop infrastructure — FuturHealth is the front-end brand, not the first-party prescribing entity
Velvet Rx
Best for: cash-pay patients comfortable with a compounded-GLP-1 telehealth model who prioritize three publicly-listed SKUs and bundled shipping over LegitScript / NABP certification, named pharmacy partner, or per-state availability verification
Velvet Rx (velvetrx.com) is a cash-pay telehealth platform offering compounded semaglutide, compounded tirzepatide, and an oral GLP-1 across three publicly-listed SKUs ranging from $139 to $199 'today' (first-month promo) with regular monthly prices of $299 / $359 / $349. Plans bundle a doctor consult, written prescription, 4 weeks of medication, free 1-2 day shipping, and 24/7 medical team access. Cash only; FSA/HSA eligible.
Score Breakdown
Pros
- ✓Publicly-disclosed pricing across 3 SKUs (semaglutide injection $299, tirzepatide injection $359, Oral GLP-1 $349) — uncommon transparency in the compounded telehealth segment
- ✓First-month promo pricing displayed verbatim on home: $139 sema / $199 tirz / $189 oral
- ✓Doctor consult, prescription, 4 weeks of medication, AND free 1-2 day shipping all included in single monthly price (verbatim: 'Same price, every dose. No hidden fees')
- ✓FSA / HSA eligibility claimed verbatim on the home
- ✓Three modalities under one roof: injectable sema, injectable tirz, and an oral GLP-1 option
- ✓No insurance accepted — fully cash-pay model with no membership fee disclosed
Cons
- ✗Oral GLP-1 SKU does NOT name the specific drug (Rybelsus? Foundayo? compounded oral semaglutide? — not disclosed) — material transparency gap given the three are clinically distinct (Rybelsus is T2D-indicated only, Foundayo is FDA-approved for chronic weight management, compounded oral has unsettled regulatory status)
- ✗No LegitScript Certified or NABP .pharmacy seal displayed on home or footer
- ✗No legal entity name disclosed publicly (footer reads only 'Copyright © 2025 VelvetRx')
- ✗No physical address disclosed publicly
- ✗No partner pharmacy named — does NOT disclose which 503A or 503B compounding pharmacy fills prescriptions
- ✗States available NOT enumerated — no state-by-state availability disclosure
- ✗Pricing display has internal inconsistency: hero shows '$299 $139 today' for sema; pricing card adds 'Save $60 instantly on your first month, then $100 off each month' which would imply $239 first / $199 ongoing — different math than the headline $139
- ✗Marketing claims include unverifiable percentages ('92% of patients are on track by month one,' '15% average body weight loss in first 90 days,' '9/10 patients say it's the most effective treatment they've ever tried') with no cited methodology, sample size, or independent audit
- ✗No FDA warning letters found for 'Velvet Rx' or 'VelvetRx' in the FDA warning-letter database as of 2026-05-10 — but this absence is not affirmative evidence of pharmacy quality
PauseRX
Best for: Buyers who value **supply-chain transparency** — PauseRX's explicit disclosure of the 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) + physician network (Beluga Health) + corporate entity (PauseRX, Inc.) is significantly above the typical DTC GLP-1 platform floor and lets buyers independently verify the clinical and dispensing pipeline. Strong fit for buyers comfortable with cash-pay (no insurance), async telehealth, and the restrictive no-cancellation policy. NOT a menopause-specific platform despite the brand name — buyers seeking that focus should look at Alloy, Midi Health, or Hers Menopause.
PauseRX (pauserx.com — legal entity 'PauseRX, Inc.') is a nationwide DTC compounded GLP-1 telehealth platform with **explicit 503A pharmacy partner disclosure** (Strive Pharmacy, 275 E Baseline Rd #104, Gilbert AZ 85233) and **explicit physician-network disclosure** (Beluga Health, belugahealth.com) — both significantly above the typical DTC platform transparency floor. Verbatim FDA compounded-medication disclaimer published verbatim: 'Compounded medications, where prescribed, are patient-specific and compounded in a licensed 503(A) compounding pharmacy. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality.' Despite the 'Pause' name evoking menopause, the FAQ confirms the site is NOT formally positioned as menopause-specific — it emphasizes weight loss (GLP-1), performance (Sermorelin), longevity (NAD+), and antioxidants (Glutathione). Products: Personalized GLP-1 (contains semaglutide) at 'All doses at $199'/mo flat; Personalized GLP-1/GIP (contains tirzepatide) 'Starting at $249'/mo; brand Wegovy, Wegovy Pill, Zepbound, and Foundayo consultations also offered. LegitScript badge displayed (ID not specified in FAQ). Cancellation: 'Orders begin processing immediately after they are placed. As a result, we are unable to change or cancel them once submitted. Medications are not able to be returned or exchanged.' Billed when meds ship. Insurance NOT accepted. 18+ only. Async telehealth model with potential video/chat requirement in some states. Phone: (844) 917-2873. Email: hello@pauserx.com. NOT disclosed: state-by-state coverage list, named medical director, LegitScript ID number, HSA/FSA eligibility, corporate physical address. Live-verified 2026-05-20.
Score Breakdown
Pros
- ✓**Explicit 503A pharmacy partner disclosure (Strive Pharmacy, Gilbert AZ 85233)** — genuinely uncommon. Buyers can independently verify Strive Pharmacy's licensure + 503A status. Removes the typical DTC marketplace abstraction.
- ✓**Explicit physician-network disclosure (Beluga Health)** — buyers can research the clinical platform handling their prescriptions. Significantly above the 'certified healthcare providers' generic-language floor.
- ✓**Verbatim FDA compounded-medication disclaimer published** — meets WLR transparency standard for compounded-product communication
- ✓**Corporate legal entity disclosed (PauseRX, Inc.)** — uncommon for DTC GLP-1 platforms
- ✓$199 flat 'all doses' compounded sema pricing removes per-tier escalation
- ✓Billing at ship (not at order) reduces upfront cash exposure
- ✓LegitScript badge displayed (verification posture present even if ID not numbered in FAQ)
- ✓Adjunct longevity products (NAD+, Glutathione, Sermorelin) for buyers seeking broader wellness stack within one platform
Cons
- ✗**State-by-state coverage list NOT enumerated** — site claims nationwide but specific state availability requires contacting support
- ✗**Cancellation policy is restrictive: 'unable to change or cancel once submitted. Medications are not able to be returned or exchanged.'** — buyers who change their mind after placing an order have no recourse
- ✗**Named medical director / clinical lead NOT disclosed** by name despite Beluga Health network disclosure (Beluga is the network, not a named MD)
- ✗**LegitScript ID NUMBER not specified in FAQ** — badge is displayed but the verifiable certification number is not surfaced, preventing direct lookup
- ✗Insurance NOT accepted — cash-pay only
- ✗HSA/FSA eligibility NOT confirmed in FAQ
- ✗Corporate physical address NOT provided (only Strive Pharmacy + Beluga Health addresses)
- ✗Despite the 'Pause' brand name, the platform is NOT formally positioned as menopause/perimenopause-specific — buyers seeking menopause-focused clinical care should look at dedicated menopause platforms
- ✗Brand Wegovy + Zepbound + Foundayo are 'consultations' (not direct dispensing) — fulfillment depends on the brand-drug supply chain elsewhere
HealthHub
Best for: Patients seeking a LegitScript-verifiable GLP-1 telehealth platform with maximum pharmacy-partner transparency (six named 503A-pattern compounders disclosed) and an oral dissolving tablet form factor for compounded semaglutide/tirzepatide, who are willing to sign up to see pricing.
HealthHub (healthhub.care) is a LegitScript-certified GLP-1 telehealth platform with verified ID 46103909, offering compounded semaglutide and tirzepatide in oral dissolving tablet (ODT) form factor. Six named 503A-pattern compounding pharmacy partners are disclosed verbatim: AnazaoHealth (Tampa FL), Tailor Made Compounding (Nicholasville KY), Redrock Pharmacy (Springville UT), Professional Arts (Lafayette LA), Perfect RX (Bartonville TX), and Vios Compounding Pharmacy (Livonia MI). Positions itself as 'a seamless blend of certified providers, in-house pharmacy and personalized care, at prices you'll love' with 'no subscriptions required' framing. Pricing is NOT itemized publicly — the site states 'transparent pricing' and 'one-time pricing that includes consults, medication, and delivery with no hidden fees' but per-drug rates are gated. A 50%-off first-order coupon (HealthHub50) is advertised. Full state list, named medical director, 503A vs 503B designation per pharmacy, governing law, and refund policy details are not publicly disclosed. Live-verified 2026-05-19.
Score Breakdown
Pros
- ✓LegitScript Certified with visible verification link (ID 46103909) — unique verifiable signal vs competitors that only display the badge
- ✓SIX named 503A-pattern pharmacy partners with city/state disclosure (AnazaoHealth Tampa FL, Tailor Made Nicholasville KY, Redrock Springville UT, Professional Arts Lafayette LA, Perfect RX Bartonville TX, Vios Livonia MI) — highest pharmacy-partner transparency in the WLR directory
- ✓Oral dissolving tablet (ODT) form factor for both semaglutide and tirzepatide (rare in DTC market)
- ✓'No subscriptions required' framing — lower commitment vs auto-renewal competitors
- ✓Cancellation policy linked publicly
Cons
- ✗Per-drug pricing NOT disclosed on the homepage — gated behind sign-up flow
- ✗Named medical director NOT disclosed (only 'board-certified providers' generic claim)
- ✗Corporate legal entity (LLC/Inc/PC) NOT disclosed in footer or terms
- ✗Full states-served list NOT disclosed (only testimonial cities visible: Austin TX, Miami FL, Denver CO)
- ✗503A vs 503B designation NOT stated per pharmacy partner
- ✗FDA compounded-medication disclaimer NOT published verbatim on accessible pages
- ✗ODT form factor for GLP-1s has weaker comparative-efficacy evidence vs injectable (no STEP/SURMOUNT-equivalent oral compounded trials)
GetRelief Rx
Best for: buyers specifically seeking sublingual (non-injectable) compounded GLP-1 drops who understand the bioavailability trade-offs and lack of human PK data for this formulation
Get Relief RX, LLC (getreliefrx.com) is a Billings, Montana-based telehealth offering compounded SUBLINGUAL semaglutide (6mg, 9mg) and compounded SUBLINGUAL tirzepatide (7.5mg, 13mg, 16mg). NPI 1306697834. BBB accredited (A rating, March 2026). Free online assessment by licensed provider. Multi-state operations (20+ states). Sublingual drops only — no injectable or FDA-approved brand-name options.
Score Breakdown
Pros
- ✓Both compounded semaglutide and tirzepatide available at publicly displayed pricing — no login wall to see costs
- ✓BBB accredited with A rating (March 2026); NPI 1306697834 is independently verifiable
- ✓Free online assessment — no upfront consultation fee before prescribing decision
Cons
- ✗SUBLINGUAL ONLY — no injectable option. Sublingual compounded semaglutide and tirzepatide have NOT been tested in human pharmacokinetic studies; mouse models suggest 5-8x higher doses needed to match subcutaneous bioavailability. Readers should understand this is NOT the same delivery method studied in STEP/SURMOUNT trials.
- ✗REGULATORY FLAG: GetReliefRX continues to offer compounded tirzepatide as of April 2026, after FDA ended enforcement discretion for tirzepatide compounding (March 19, 2025 for 503B, April 22, 2025 for 503A). The legal basis may be state-level exemptions, but this is not publicly disclosed on the site.
- ✗No LegitScript, PCAB, or NABP certifications identified — BBB accreditation is not a pharmacy-specific compliance credential
- ✗Prescriber credentials are described generically as 'licensed clinicians' without specifying MD/DO/NP/PA breakdown
Ark Health
Best for: Buyers seeking the **broadest single-platform product menu** (compounded + brand + non-GLP-1 wellness adjuncts like Sermorelin and MIC/B12 all under one account) who can tolerate the transparency gaps (no states list, no LegitScript ID, no named pharmacy partner). NOT recommended for buyers seeking brand Ozempic/Mounjaro — direct manufacturer channels (NovoCare, LillyDirect) are 2-3× cheaper. Best value tier is the compounded oral sema at $125/mo. Note: states-served gap means buyers should call (855) 758-2275 to confirm coverage before signing up.
Ark Health (tryark.com) is a national direct-to-consumer GLP-1 telehealth platform offering an unusually **broad product menu** — compounded semaglutide injection ($169/mo discounted), compounded tirzepatide injection ($249/mo discounted), compounded oral semaglutide ($125/mo discounted), brand Ozempic ($1,399/mo cash), brand Mounjaro ($1,499/mo cash), plus injectable Sermorelin ($220/mo) and injectable MIC/B12 ($220/mo). Brand cash pricing is significantly higher than direct pharmacy/coupon channels — DTC brand pricing through Ark Health is NOT competitive with NovoCare or LillyDirect. Compounded tier is the value play. **'100% online consultations with certified healthcare providers'** — sync vs async not explicitly stated. Verbatim marketing claims: 'Free expedited shipping,' 'Consistent pricing at all dosages,' 'No hidden fees,' 'Continuous support and follow-ups.' Phone: (855) 758-2275. Email: support@tryark.com. Significant gaps in public disclosure: states served NOT enumerated, LegitScript certification ID NOT visible, verbatim FDA compounded-medication disclaimer NOT displayed on homepage/FAQ, named medical director NOT disclosed, pharmacy partner (503A/503B) NOT named, HSA/FSA eligibility NOT confirmed, corporate legal entity NOT specified, corporate address NOT provided, refund/cancellation policy linked but text not surfaced on browseable pages. Live-verified 2026-05-20.
Score Breakdown
Pros
- ✓**Broadest product menu in the directory** — compounded sema injection + compounded tirz injection + compounded oral sema + brand Ozempic + brand Mounjaro + Sermorelin + MIC/B12 all under one platform. Buyers wanting optionality (try compounded, switch to brand, add adjuncts) can stay within one telehealth account.
- ✓**'Consistent pricing at all dosages'** — flat-rate model removes per-tier price escalation as patients titrate up (typical DTC pattern is $99→$200+ as dose increases)
- ✓Compounded oral semaglutide at $125/mo is competitively priced for the oral-tier niche (most DTC providers do not offer oral compounded sema)
- ✓Free expedited shipping included
- ✓Phone support published (uncommon among DTC platforms)
Cons
- ✗**States served NOT publicly enumerated** — buyers cannot confirm coverage in their state without contacting support. This is a CRITICAL transparency gap.
- ✗**LegitScript certification status NOT disclosed** — no badge or verifiable ID visible on homepage/FAQ. Cannot independently confirm compliance posture.
- ✗**Verbatim FDA compounded-medication disclaimer NOT displayed** on homepage/FAQ — falls short of FDA guidance + WLR transparency standard
- ✗**Named medical director / clinical lead NOT disclosed** — only 'certified healthcare providers' generic
- ✗**Pharmacy partner NOT named** — 503A vs 503B compounding designation unspecified. Cannot trace supply chain.
- ✗**Brand Ozempic ($1,399) and Mounjaro ($1,499) DTC cash pricing significantly markup vs direct channels** — NovoCare Ozempic baseline is $499/mo without insurance for cash buyers; LillyDirect Zepbound is $349-$549/mo. Buying brand drugs through Ark Health DTC is materially more expensive than direct manufacturer/pharmacy channels.
- ✗Corporate legal entity (LLC/Inc/PC) NOT disclosed
- ✗Corporate address NOT provided
- ✗Refund/cancellation policy linked but text not surfaced on browseable pages
- ✗HSA/FSA eligibility NOT confirmed
- ✗Synchronous vs asynchronous telehealth model NOT explicitly stated
MadeMed
Best for: Patients seeking a LegitScript-badged DTC platform with both injection and oral form factors for compounded semaglutide and tirzepatide, who are comfortable with pricing gated behind sign-up and limited public supply-chain disclosure.
MadeMed (mademed.com) is a direct-to-consumer GLP-1 telehealth platform offering compounded semaglutide and tirzepatide in BOTH injectable and oral form factors — four distinct products listed in the homepage navigation: Injectable Semaglutide, Oral Semaglutide, Injectable Tirzepatide, Oral Tirzepatide. Site displays a LegitScript certification badge (specific ID not publicly disclosed on homepage). Customer phone support: +1 (800) 582-1428. Corporate copyright shows '© 2026 MadeMed' but no LLC/Inc/PC designation. Pricing is gated behind product-page or checkout flow — not itemized on the public landing page. States served, named pharmacy partner, 503A vs 503B designation, FDA compounded-medication disclaimer text, named medical director, governing law, and itemized refund policy are not publicly disclosed. Affiliate partnership via Katalys (RevOffers offer ID 1536). Live-verified 2026-05-19.
Score Breakdown
Pros
- ✓Four distinct product offerings (injection + oral for both semaglutide and tirzepatide) gives needle-averse patients more options than most DTC competitors
- ✓LegitScript certification badge displayed on homepage
- ✓Customer phone support published (1-800-582-1428) — uncommon transparency vs chat-only competitors
- ✓Affiliate partnership available via Katalys network (RevOffers offer ID 1536)
Cons
- ✗Pricing NOT disclosed on the public homepage or product nav — fully gated behind product-page or checkout flow
- ✗LegitScript ID NUMBER not publicly displayed (only the certification badge)
- ✗Pharmacy partner NOT named
- ✗States-served list NOT disclosed publicly
- ✗Named medical director / clinician leadership NOT disclosed
- ✗503A vs 503B compounding designation NOT specified
- ✗Corporate legal entity (LLC/Inc/PC) NOT disclosed
- ✗FDA compounded-medication disclaimer NOT visible on indexable HTML (site appears JavaScript-rendered)
- ✗Governing law / arbitration venue NOT disclosed
- ✗Oral compounded GLP-1 forms have weaker evidence base vs injectable (no STEP/SURMOUNT-equivalent oral compounded RCTs)
Direct Meds
Best for: listed for transparent disclosure — see FDA warning and BBB complaint pattern before considering
Direct Meds is a Utah-based telehealth provider offering compounded semaglutide and tirzepatide in injection and sublingual formats. Listed here with full disclosure of a September 2025 FDA warning letter for misleading marketing, plus a documented pattern of customers reporting unexpected 3-month commitment charges — see warnings and cons before considering.
Score Breakdown
Pros
- ✓Both semaglutide and tirzepatide available in injection and sublingual formats
- ✓All-inclusive pricing with medication, consultations, supplies, and 1–2 day temperature-controlled shipping
- ✓LegitScript certification confirmed (verified December 2025)
- ✓Named 503A pharmacy partners: CraftedRx (Warrenton, MO) and ChemistryRx (Folcroft, PA)
Cons
- ✗FDA warning letter September 9, 2025 for misleading marketing of compounded GLP-1s as equivalent to FDA-approved drugs — compliance status post-warning not publicly documented
- ✗Extensive Better Business Bureau complaint pattern (rating 1.12/5 across 226 reviews as of April 2026) documenting a hidden 3-month commitment trap: multiple users report being charged $940+ for a 3-month supply when they believed they were purchasing 1 month. Direct Meds disputes the characterization but the complaint volume is material
- ✗Katalys program name 'Direct Meds GLP-1 Offers Top Funnels' and $280 CPA payout indicate aggressive performance-marketing optimization, which can correlate with conversion-first UX patterns
- ✗Rating discrepancy: Trustpilot 4.6/5 from 7,500+ reviews vs. BBB 1.12/5 from 226 reviews — suggests either review-solicitation bias or genuine unresolved customer experience issues
- ✗Not available in Mississippi, Louisiana, or California
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Incorporated May 2024 — less than 2 years of operational history
- ✗Auto-renewal continues until manual email cancellation; BBB complaints report retention-department friction and hold times exceeding 15 minutes
Related Rankings
Frequently Asked Questions
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.